{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:23:00Z","timestamp":1788870180341,"version":"build-2803163510"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,10,23]],"date-time":"2001-10-23T00:00:00Z","timestamp":1003795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["BE 890\/5-3"],"award-info":[{"award-number":["BE 890\/5-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The tumor\u2010suppressor genes p14(ARF), p16(INK4a) and Tp53 are commonly inactivated in many tumors. We investigated their role in the pathogenesis of 9 bile tract cancer cell lines and 21 primary sporadic extrahepatic bile duct carcinomas. p53 and p16 protein expression was examined by Western blot analysis and immunohistochemistry. Mutation screening of p53 was done by SSCP and direct sequencing. Inactivating mechanisms of p14 and p16 were addressed by screening for mutations, homozygous deletions, chromosomal loss of 9p21 (loss of heterozygosity [LOH] analysis) and promoter hypermethylation of the p14\/p16 genes. p53 overexpression could be detected in 7 of 9 cell lines and 7 of 21 primary tumors, but mutations were found in 3 cell lines only. p16 expression was absent in all cell lines, due to homozygous deletion of the gene in 8 of 9 cell lines and hypermethylation of the p16 promoter in one cell line (CC\u2010LP\u20101). p14 exon 1\u03b2 was homozygously deleted in 6 of 9 cell lines, while retained in CC\u2010LP\u20101 and 2 additional lines. No p14 promoter hypermethylation could be detected. p16 expression was lost in 11 of 21 primary tumors. p16 promoter hypermethylation was present in 9 of 21 primary tumors, all with lost p16 expression. Allelic loss at 9p21 was detected in 13 of 21 primary tumors, 10 of 11 with lost p16 expression and 8 of 9 with methylated p16 promoter. No p14 promoter hypermethylation or p14\/p16 mutations could be detected. Neither Tp53 nor p16 alterations showed obvious association with histopathologic or clinical characteristics. In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. Therefore, p16, but not p14, seems to be the primary target of inactivation at the INK4a locus in bile duct cancers. Other mechanisms than Tp53 mutations seems to be predominantly responsible for stabilization of nuclear p53 protein in bile duct cancers. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.1639","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T12:33:59Z","timestamp":1030278839000},"page":"481-488","source":"Crossref","is-referenced-by-count":33,"title":["Inactivation of the INK4a\/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines"],"prefix":"10.1002","volume":"97","author":[{"given":"Karel","family":"Caca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Feisthammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Klee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Witzigmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wittekind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"M\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Berr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920915)70:6<1498::AID-CNCR2820700609>3.0.CO;2-C"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910283411807"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199103000-00010"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<26::AID-CNCR5>3.0.CO;2-K"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.6.852"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310205"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70537-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90186-I"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)80071-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-200003000-00007"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90200-3"},{"key":"e_1_2_6_13_2","first-page":"477","article-title":"Mutation of p53 and K\u2010ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma","volume":"79","author":"Kang YK","year":"1999","journal-title":"Lab Invest"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940080415"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<695::AID-IJC5>3.0.CO;2-8"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1996.tb03546.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1197"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(98)00017-1"},{"key":"e_1_2_6_19_2","first-page":"129","article-title":"Hypermethylation\u2010associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status","volume":"60","author":"Esteller M","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.1016"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2744(200101)30:1<26::AID-MC1010>3.0.CO;2-E"},{"key":"e_1_2_6_22_2","first-page":"2756","article-title":"Mutations of p16Ink4\/CDKN2 and p15Ink4B\/MTS2 genes in biliary tract cancers","volume":"55","author":"Yoshida S","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.5.721"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.1999.5615"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9821"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81400-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.1.22"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90214-7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.11.6457"},{"key":"e_1_2_6_30_2","first-page":"1","article-title":"In vitro interaction of \u03b1\u2010difluoromethyl\u2010ornithine (DFMO) and human recombinant interferon\u2010\u03b3 (rIFN\u2010\u03b3) on human cancer cell lines","volume":"175","author":"Scherdin G","year":"1987","journal-title":"Immunobiology"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.177.61"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910520217"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(85)80002-7"},{"key":"e_1_2_6_34_2","first-page":"345","article-title":"Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma\u2010derived model","volume":"68","author":"Purdum PPD","year":"1993","journal-title":"Lab Invest"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.355"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250613"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.5.1773"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.11.2057"},{"key":"e_1_2_6_39_2","first-page":"591","article-title":"Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia","volume":"58","author":"Myohanen SK","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_6_40_2","first-page":"881","article-title":"p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence","volume":"10","author":"Niewolik D","year":"1995","journal-title":"Oncogene"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.44"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(200003)190:4<450::AID-PATH545>3.0.CO;2-8"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.4065\/70.5.425"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-210"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0994-15"},{"key":"e_1_2_6_46_2","first-page":"3126","article-title":"Abrogation of the Rb\/p16 tumor\u2010suppressive pathway in virtually all pancreatic carcinomas","volume":"57","author":"Schutte M","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8153634"},{"key":"e_1_2_6_48_2","first-page":"2041","article-title":"p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression","volume":"12","author":"Larsen CJ","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_6_49_2","first-page":"2704","article-title":"Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma","volume":"5","author":"Xing EP","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90126-5"},{"key":"e_1_2_6_51_2","first-page":"71","article-title":"K\u2010ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients","volume":"29","author":"Petmitr S","year":"1998","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2000.00717.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1996.tb03110.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<158::AID-JSO9>3.0.CO;2-N"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<86::AID-CNCR10>3.0.CO;2-9"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220313"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1996.tb00712.x"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940901)74:5<1542::AID-CNCR2820740508>3.0.CO;2-U"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60253-5"},{"key":"e_1_2_6_60_2","first-page":"681","article-title":"p53 gene mutations inside and outside of exons 5\u20138: the patterns differ in breast and other cancers","volume":"10","author":"Hartmann A","year":"1995","journal-title":"Oncogene"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90639-T"},{"key":"e_1_2_6_62_2","first-page":"4740","article-title":"Inactivation of the p16 (INK4A) tumor\u2010suppressor gene in pancreatic duct lesions: loss of intranuclear expression","volume":"58","author":"Wilentz RE","year":"1998","journal-title":"Cancer Res"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.1639","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.1639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:09:30Z","timestamp":1697548170000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.1639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,29]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1002\/ijc.1639"],"URL":"https:\/\/doi.org\/10.1002\/ijc.1639","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,29]]}}}